Cancer Science & Therapy

Monte S. Willis

Publications

• Research Article
  Selective Inhibition of NF-kappa-B with NBD Peptide Reduces Tumor- Induced Wasting in a Murine Model of Cancer Cachexia In vivo
  Author(s): Ashley Wysong, Scott A. Asher, Xiaoying Yin, Mitchell R. Gore, Lisa Weinstein, Denis C. Guttridge, Albert S. Baldwin, Marion E. Couch and Monte S. WillisAshley Wysong, Scott A. Asher, Xiaoying Yin, Mitchell R. Gore, Lisa Weinstein, Denis C. Guttridge, Albert S. Baldwin, Marion E. Couch and Monte S. Willis
  
  Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation, which is seen in as many as 80% of patients with advanced malignancy. It accounts for an estimated 20-30% of all cancer-related deaths. The mechanism by which cancer induces skeletal muscle atrophy in cachexia involves tumor-derived cytokines, including TNF?, IL-1, and IL-6. Upon interaction with their unique receptors on skeletal muscle, these cytokines activate NF-kappaB, a transcription factor crucial for atrophy related sarcomere proteolysis to occur. The significance of NF-?B is highlighted in studies demonstrating that genetic inhibition of NF-?B ameliorates cancer-induced muscle loss in vivo. In the present study, we evaluate a selective NF-kappaB inhibitor (NBD peptide) which targets the IkappaB complex to prevent cancer-induced skeletal muscle atroph.. Read More»
  DOI: 10.4172/1948-5956.1000052

  Abstract PDF